公司團隊

一致的願景，一項使命，一個團隊

我們的領導

周礪寒博士

執行董事，聯合創始人兼執行總裁

鄒瑞陽博士

執行董事，聯合創始人兼首席技術官

Isaac Ho

執行董事兼首席投資官

Choo Beng Lor

首席財務官

羅文達

首席投資者關係官兼香港區董事總經理

Vitoria Owyong

總法律顧問兼公司祕書

我們的顧問

我們的科學顧問委員會 (SAB) 對我們的研發活動和策略提供外部科學審查。

MiRXES （覓瑞）SAB 由 覓瑞 聯合創始人和首席科學顧問 朱興奮教授主持。

Prof. Too Heng-Phon

PhD

Associate Professor of Biochemistry, National University of Singapore

Associate Professor of Chemical and Biomolecular Engineering, National University of Singapore

Co-founder & Chief Scientific Advisor, MiRXES

Prof. Frank Slack

PhD

Shields Warren Mallinckrodt Professor of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center

Director, Harvard Medical School Initiative for RNA Medicine at Beth Israel Deaconess Medical Center

Co-discoverer of the second known microRNA and the first human microRNA

Prof. Chng Wee Joo

MB ChB, PhD, MRCP, DipRCPath, MRCPath

Director, National University Cancer Institute, National University Health System

Group Director of Research, National University Health System

Deputy Director & Senior Principal Investigator, Cancer Science Institute, Singapore

Vice Dean of Research & Provost’s Chair Professor, Yong Loo Lin School of Medicine, National University of Singapore

Chief Medical Advisor, MiRXES

Prof. Lam Kong Peng

PhD

Professor of Microbiology and Immunology, National University of Singapore

Executive Director, Singapore Immunology Network, A*STAR

Prof. Takahiro Ochiya

PhD

Professor of Molecular and Cellular Medicine, Institute of Medical Science, Tokyo Medical University

Chief Scientific Officer, Theoria Science

President, Japanese Society for Extracellular Vesicles

Prof. Yeoh Khay Guan

MBBS, MMed, FRCP (London), FRCP (Glasg), FAMS

Irene Tan Liang Kheng Professor in Medicine and Oncology, National University of Singapore

Senior Consultant, Gastroenterology and Hepatology, National University Hospital

Lead Principal Investigator, Singapore Gastric Cancer Consortium

Chairman, National Colorectal Cancer Screening Committee, Health Promotion Board, Ministry of Health, Singapore

Chief Executive, National University Health System

Senior Vice President (Health Affairs), National University of Singapore

Dr. Holger Heyn

PhD

Leader, Single Cell Genomics Team, Spanish National Centre for Genomic Analysis (CNAG-CRG), Barcelona, Spain

Scientific Co-founder, Omniscope

Prof. Tony Mok

BMSc, MD, FRCP(C), FRCP(Edin), FRCP(Lond), FHKCP, FHKAM(Medicine), FASCO, Member of ASHK

Chairman of the Department of Clinical Oncology, The Chinese University of Hong Kong

Li Shu Fan Professor of Clinical Oncology, The Chinese University of Hong Kong

Past President, International Association for the Study of Lung Cancer (IASLC)

社交媒体

公司簡介

解決方案

技術

研發管綫

新聞發佈室

Copyright © 2022 MiRXES Pte Ltd. All rights reserved. | Privacy Policy
Scroll to Top

Zhou Lihan

Ph.D.

Executive Director, Co-founder & Chief Executive Officer

Zhou Lihan is the Executive Director, Co-founder and Chief Executive Officer of MiRXES. Lihan led MiRXES’ growth from a 3-man start-up in Singapore to a leader in RNA technology and disease early detection with operations globally.

Prior to founding MiRXES, Lihan led a research team at the Bioprocessing Technology Institute, A*STAR to develop a novel microRNA qPCR assay platform for biomarker and therapeutic target discovery. In 2015, Lihan was recognized by the MIT Technology Review as a member of the Innovators Under 35.

Lihan obtained his Ph.D. in Biochemistry from Yong Loo Lin School of Medicine, National University of Singapore. Lihan has authored and co-authored more than 20 peer-reviewed publications and several patent applications.

Zou Ruiyang

Ph.D.

Executive Director, Co-founder & Chief Technology Officer

Zou Ruiyang is Executive Director, Co-founder and Chief Technology Officer of MiRXES. Ruiyang is responsible for MiRXES’s technology and diagnostic test development, and also oversees MiRXES’s China operations.

Prior to founding MiRXES, he was the Head of Bioinformatics at the MicroRNA Signature Identification Center, A*STAR. Ruiyang has a passion for science and is continuously innovating to discover technology that can be developed to practical applications that can be delivered to the public.

Ruiyang has a PhD in Chemical and Pharmaceutical Engineering from Singapore-MIT Alliance (NUS-MIT), Singapore. He also successfully completed his dual degree in 2007 where he attained Bachelor of Science, Molecular Science and Engineering, Nankai University, Tianjin, P. R. China, and Bachelor of Engineering, Molecular Science and Engineering, Tianjin University, Tianjin, P. R. China. Ruiyang has co-authored more than 10 publications and has eight patents and applications.

Isaac Ho

Executive Director and Chief Investment Officer

Isaac Ho is Executive Director and Chief Investment Officer of MiRXES where he oversees corporate development, investor relations as well as builds strategic partnerships with key healthcare players and financial institutions.

Prior to MiRXES, Isaac founded Singapore Health, and subsequently VentureCraft Group, a Singapore government accredited co-investment partner and incubator in the healthcare and biomedical sciences sector. He is a veteran in entrepreneurship, investment, and business management. Under his leadership, Venturecraft Group was appointed as an accelerator under SPRING Singapore’s Sector Specific Accelerator Program for Biomedical Sciences.

Isaac graduated from Deakin University with a Bachelor’s Degree in Commerce (Marketing and Management).

Choo Beng Lor

Chief Financial Officer

Choo Beng Lor is the Chief Financial Officer of MiRXES and is responsible for matters relating to finance, internal controls, compliance, corporate management and investor relations.

He was previously with Zheneng Jinjiang Environment Holding Company Limited where he was the Financial Controller overseeing matters relating to financial management and reporting, compliance with post-listing obligations. Prior to that, Beng Lor spent 11 years being a CFO for companies including Cima NanoTech Pte Ltd, Sound Global Ltd and Sino Chemical Holdings Pte Ltd.

Beng Lor graduated with a Bachelor of Accountancy from Nanyang Technological University, Singapore. He is a Chartered Accountant of the Institute of Singapore Chartered Accountants.

Martin Law

Chief Investor Relations Officer & Managing Director, Hong Kong

Martin Law is the Chief Investor Relations Officer of the MiRXES Group where he oversees investor relations, strategic communication, corporate development and M&As of the group, he also works closely with CIO & CFO on finance, investment and treasury matters.

Martin is also the Managing Director of MiRXES Hong Kong. He leads the business development, manages operations and upholds governance of MiRXES’ businesses in Hong Kong and Greater Bay Area.

Martin is a qualified accountant with over 30 years of experience in finance management, investor relations, corporate development, investment and corporate finance, in industries such as banking, insurance, and medical & healthcare. Martin was previously the Chief Financial Officer of a number of multinational corporations, including Lloyd’s of London China, ANZ Bank China, and a Hong Kong listed medical & healthcare group. Martin is currently the Independent Non-Executive Director (INED) of a dual-listed company, Liaoning Port Co. Ltd. (2180.HK/601880.SH)

Martin holds an MBA degree and is a Chartered Management Accountant (ACMA), Chartered Global Management Accountant (CGMA), Certified Information Systems Auditor (CISA), as well as an Associate of the Chartered Institute of Arbitrator (ACIArb). Martin is also a Fellow of the Hong Kong Institute of Directors (FHKIoD).

Yoong Li-Foong

Representative Director & Country General Manager, MiRXES Japan

Yoong Li-Foong is the Representative Director and Country Manager of MiRXES Japan. Li-Foong led the setting up of MiRXES subsidiary in Tokyo, Japan, where she now heads the business development and market expansion, as well as overseeing the overall operations.

She has more than 13 years of research experience in USA and Japan, including genetics, development biology and cellular signaling, and has published eight papers. Prior to joining MiRXES, Li-Foong has accumulated more than 10 years of research experience in Japan’s largest national research institute, RIKEN, where she has also received the prestigious international fellowship award from Human Frontier Science Program. She is passionate about bringing MiRXES’s innovative disease early detection solutions, from lab to user, so that more people can be benefited from a better and earlier diagnosis.

Li-Foong has a PhD in Biochemistry from the National University of Singapore.